Abstract
The human epoxide hydrolase 1 (EPHX1) is a metabolism gene, which is responsible for the first phase of the xenobiotic metabolism. The product, microsomal epoxide hydrolase (mHE), plays an important role in the detoxification of carcinogenic polycyclic aromatic hydrocarbons. Many reports also have studied the correlation between EPHX1 gene polymorphisms and development and generation of cancers. However, few of studies on EPHX1 participating in chemotherapeutics metabolism were reported. The purpose of the present study was to evaluate the prognostic significance of the EPHX1gene expression in acute myeloid leukemia (AML). Using real timeâquantitative polymerase chain reaction (RTâqPCR), mRNA expression levels of EPHX1gene was measured in bone marrow samples of newly diagnosed AML patients (n=46) and control group (n=12) without tumors. The levels expression of EPHX1 had a significant association with the treatment response and prognosis of AML patients. Additionally, the EPHX1 expression levels can aid for an improved understanding of the multidrug resistant mechanism in AML.
Highlights
Acute myeloid leukemia (AML) originates from accumulation of abnormal blasts in the marrow
Amount to 46 de novo AML patients were involved in the study. 12 of the total patients with single core binding factor (CBF) fusion gene positive, belonged to better group
The EPHX1 gene expression levels shown a significant difference between the CBF- group and control group,CBF+ group, and had no difference between CBF+ group and control group (Table 1 and Figure 2)
Summary
Acute myeloid leukemia (AML) originates from accumulation of abnormal blasts in the marrow. Diagnosis rests on demonstration that the marrow or blood has>20% blasts with specifical surface markers CD33 and CD13 [1]. With “7+3” induction, complete remission (CR) rates of 40–80% have been reported [3]. In order to improve the curative effect, people tried to increase the dose of chemotherapy, which significantly increased treatment-related deaths, CR rates but no significant improvement, relapse rates reached up to 53-60% after CR, and survival rates for 5 years was merely 22% [4]. Multidrug resistance to chemotherapy considerably reduces the rate of treatment success and increases the risk of relapse
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
